FindTrial
Sign In

Preoperative inhaled budesonide reduce the lung injury after cardiopulmonary bypass

Preoperative inhaled budesonide reduce the lung injury after cardiopulmonary bypass

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPC-15006179
Enrollment
Unknown
Registered
2015-03-31
Start date
2015-04-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung injury after CPB

Interventions

Control group:Inhaled saline
Budesonide group:Inhaled budesonide

Sponsors

The Second Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 60 Years

Inclusion criteria

Inclusion criteria: 60 patients with CPB, ASA II-III, heart function II-III, age 25 to 65 years old.

Exclusion criteria

Exclusion criteria: Excluded criteria: severe lung disease or lung dysfunction, patients with immune dysfunction,toxemia, pleural effusion, lung infection, hypoproteinemia, patients with hepatic, renal or coagulation disorder, COPD and asthma were excluded.

Design outcomes

Primary

MeasureTime frame
arterial blood gas analysis;airway pressure;IL-1;TNF-alpha;IL-6;IL-8;IL-10;elastase;—

Secondary

MeasureTime frame
iNOS;Total protein content in BAL;Cell counts in BAL;MPO;MDA;SOD;macrophage chemoattractant protein;P-selectin;CRP;C3a;C5a;duration of ventilation;—

Countries

China

Contacts

Public ContactWei Gao
gaowei20055@126.com+86 13836172191

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026